沙美特罗替卡松联合白三烯受体拮抗剂治疗对重度COPD患者稳定期IC变化的影响

摘要

Objective:To study severe Chronic obstructive pulmonary disease (COPD) patients with inhalation hormones combined LTRA and inhaled corticosteroids alone before and after the changes of the IC.Method: Selected 60 patients with moderate to severe COPD were randomly divided into observation group (n=30) and control group (n=30).The observation group was given SFC(50μg/500μg) inhaling twice daily comined with LTRA (10 mg) once daily,The control group was given SFC (500μg/50μg) twice daily. Treatment in both groups for 6 months,determined the Pulmonary function testing and IC testing before treatment and after 3 months、6 months.Over the same period using the 6 min walk distance evaluation of exercise capacity,dyspnea index mmRC evaluate the quality of life.Result:The treatment of 3 months and 6 months of observation group IC than the control group(P<0.05);in various stages of treatment dyspnea index mmRC observation group than the control group (P<0.05).Conclusion:IC lung function and quality of life of the improvement is more obvious,the early improvement in exercise tolerance in COPD.Slowing lung function decline of severe Chronic obstructive pulmonary disease (COPD) patients with inhalation hormones combined LTRA.%　　目的：研究重度慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)患者使用沙美特罗替卡松联合白三烯受体拮抗剂(Leukotriene receptor antagonists,LTRA)及单独使用沙美特罗替卡松治疗前后深吸气量的变化.方法：选取60例重度 COPD 患者随机分为观察组(n=30)及对照组(n=30),观察组给予沙美特罗替卡松(500μg/50μg)早晚各一次吸入联合白三烯受体拮抗剂(10 mg)上午口服一次,对照组给予沙美特罗替卡松沙美特罗替卡松(500μg/50μg)早晚各一次吸入,两组治疗6个月.在治疗前、治疗3个月、6个月后行肺功能检测、IC(inspiratory capacity,IC)检测；同时采用6 min 步行距离评价运动能力,呼吸困难指数 mmRC 评价生活质量.结果：在治疗3个月及6个月观察组 IC 优于对照组(P<0.05)；在各治疗阶段呼吸困难指数 mmRC 观察组均优于对照组(P<0.05).结论：沙美特罗替卡松联合白三烯受体拮抗剂治疗重度 COPD 较单用沙美特罗替卡松对 IC 肺功能和生活质量的改善作用更明显,早期改善 COPD 的运动耐量,延缓肺功能的下降.